Page 76 - EASL POSTGRADUATE COURSE
P. 76
with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188.
[24] Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2
diabetes: a meta-analysis. CMAJ 2009;180:32-39.
[25] Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic
patients in France: a population-based cohort study. Diabetologia 2012;55:1953-1962.
[26] Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled,
cumulative exposure analysis. Diabetologia 2015;58:493-504.
[27] Chalasani N,Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty
liver disease: practice Guideline by the American Association for the Study of Liver Diseases,
American College of Gastroenterology, and the American Gastroenterological Association.
Hepatology 2012;55:2005-2023.
[28] Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver
diseases. Gastroenterology 2011;140:1120-1125 e1121-1112.
[29] Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic
steatohepatitis. Drug Discov Today 2012;17:988-997.
[30] Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor
agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Gastroenterology 2013;145:574-582 e571.
[31] Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand
obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre,
randomised, placebo-controlled trial. Lancet 2014; doi: 10.1016/S0140-6736(14)61933-4.
[32] Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome.
J Clin Invest 2006;116:590-597.
[33] Bojic LA, Huff MW. Peroxisome proliferator-activated receptor delta: a multifaceted metabolic
player. Curr Opin Lipidol 2013;24:171-177.
[34] Liu S, Hatano B, Zhao M, et al. Role of peroxisome proliferator-activated receptor {delta}/{beta}
in hepatic metabolic regulation. J Biol Chem 2011;286:1237-1247.
[35] Iwaisako K, Haimerl M, PaikYH, et al. Protection from liver fibrosis by a peroxisome proliferator-
activated receptor delta agonist. Proc Natl Acad Sci U S A 2012;109:E1369-1376.
[36] Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome
proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic
fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013;58:1941-1952.
[37] Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor
alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally
obese subjects. Diabetes Care 2013;36:2923-2930.
[38] Cariou B, Zair Y, Staels B, et al. Effects of the new dual PPAR alpha/delta agonist GFT505
on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or
impaired glucose metabolism. Diabetes Care 2011;34:2008-2014.
76 Postgraduate Course Syllabus • Metabolic Liver Disease
[24] Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2
diabetes: a meta-analysis. CMAJ 2009;180:32-39.
[25] Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic
patients in France: a population-based cohort study. Diabetologia 2012;55:1953-1962.
[26] Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled,
cumulative exposure analysis. Diabetologia 2015;58:493-504.
[27] Chalasani N,Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty
liver disease: practice Guideline by the American Association for the Study of Liver Diseases,
American College of Gastroenterology, and the American Gastroenterological Association.
Hepatology 2012;55:2005-2023.
[28] Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver
diseases. Gastroenterology 2011;140:1120-1125 e1121-1112.
[29] Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic
steatohepatitis. Drug Discov Today 2012;17:988-997.
[30] Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor
agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Gastroenterology 2013;145:574-582 e571.
[31] Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand
obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre,
randomised, placebo-controlled trial. Lancet 2014; doi: 10.1016/S0140-6736(14)61933-4.
[32] Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome.
J Clin Invest 2006;116:590-597.
[33] Bojic LA, Huff MW. Peroxisome proliferator-activated receptor delta: a multifaceted metabolic
player. Curr Opin Lipidol 2013;24:171-177.
[34] Liu S, Hatano B, Zhao M, et al. Role of peroxisome proliferator-activated receptor {delta}/{beta}
in hepatic metabolic regulation. J Biol Chem 2011;286:1237-1247.
[35] Iwaisako K, Haimerl M, PaikYH, et al. Protection from liver fibrosis by a peroxisome proliferator-
activated receptor delta agonist. Proc Natl Acad Sci U S A 2012;109:E1369-1376.
[36] Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome
proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic
fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013;58:1941-1952.
[37] Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor
alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally
obese subjects. Diabetes Care 2013;36:2923-2930.
[38] Cariou B, Zair Y, Staels B, et al. Effects of the new dual PPAR alpha/delta agonist GFT505
on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or
impaired glucose metabolism. Diabetes Care 2011;34:2008-2014.
76 Postgraduate Course Syllabus • Metabolic Liver Disease
